

References

R-5043

1. Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. May 18 2002; 359(9319): 1734-9. PMID 12049862
2. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. May 2002; 35(5): 1164-71. PMID 11981766
3. Tao R, Li X, Ran R, et al. A mixed analysis comparing nine minimally invasive surgeries for unresectable hepatocellular carcinoma patients. Oncotarget. Jan 17 2017; 8(3): 5460-5473. PMID 27705924
4. Pollock RF, Brennan VK, Shergill S, et al. A systematic literature review and network meta-analysis of first-line treatments for unresectable hepatocellular carcinoma based on data from randomized controlled trials. Expert Rev Anticancer Ther. Mar 2021; 21(3): 341-349. PMID 33131346
5. Venerito M, Pech M, Canbay A, et al. NEMESIS: Noninferiority, Individual-Patient Metaanalysis of Selective Internal Radiation Therapy with 90 Y Resin Microspheres Versus Sorafenib in Advanced Hepatocellular Carcinoma. J Nucl Med. Dec 2020; 61(12): 1736-1742. PMID 32358087
6. Yang B, Liang J, Qu Z, et al. Transarterial strategies for the treatment of unresectable hepatocellular carcinoma: A systematic review. PLoS One. 2020; 15(2): e0227475. PMID 32074102
7. Ludwig JM, Zhang D, Xing M, et al. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus 90 Y-radioembolization for hepatocellular carcinoma. Eur Radiol. May 2017; 27(5): 2031-2041. PMID 27562480
8. Lobo L, Yakoub D, Picado O, et al. Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis. Cardiovasc Intervent Radiol. Nov 2016; 39(11): 1580-1588. PMID 27586657
9. Facciorusso A, Serviddio G, Muscatello N. Transarterial radioembolization vs chemoembolization for hepatocarcinoma patients: A systematic review and meta-analysis. World J Hepatol. Jun 28 2016; 8(18): 770-8. PMID 27366304
10. Vente MA, Wondergem M, van der Tweel I, et al. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol. Apr 2009; 19(4): 951-9. PMID 18989675
11. Dhondt E, Lambert B, Hermie L, et al. 90 Y Radioembolization versus Drug-eluting Bead Chemoembolization for Unresectable Hepatocellular Carcinoma:

- Results from the TRACE Phase II Randomized Controlled Trial. *Radiology*. Jun 2022; 303(3): 699-710. PMID 35258371
12. Facciorusso A, Bargellini I, Cela M, et al. Comparison between Y90 Radioembolization Plus Sorafenib and Y90 Radioembolization alone in the Treatment of Hepatocellular Carcinoma: A Propensity Score Analysis. *Cancers (Basel)*. Apr 07 2020; 12(4). PMID 32272656
13. Padia SA, Johnson GE, Horton KJ, et al. Segmental Yttrium-90 Radioembolization versus Segmental Chemoembolization for Localized Hepatocellular Carcinoma: Results of a Single-Center, Retrospective, Propensity Score-Matched Study. *J Vasc Interv Radiol*. Jun 2017; 28(6): 777-785.e1. PMID 28365172
14. Soydal C, Arslan MF, Kucuk ON, et al. Comparison of survival, safety, and efficacy after transarterial chemoembolization and radioembolization of Barcelona Clinic Liver Cancer stage B-C hepatocellular cancer patients. *Nucl Med Commun*. Jun 2016; 37(6): 646-9. PMID 26905317
15. Oladeru OT, Miccio JA, Yang J, et al. Conformal external beam radiation or selective internal radiation therapy-a comparison of treatment outcomes for hepatocellular carcinoma. *J Gastrointest Oncol*. Jun 2016; 7(3): 433-40. PMID 27284477
16. Gramenzi A, Golfieri R, Mosconi C, et al. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. *Liver Int*. Mar 2015; 35(3): 1036-47. PMID 24750853
17. Kulik L, Heimbach JK, Zaiem F, et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis. *Hepatology*. Jan 2018; 67(1): 381-400. PMID 28859222
18. Salem R, Gordon AC, Mouli S, et al. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. *Gastroenterology*. Dec 2016; 151(6): 1155-1163.e2. PMID 27575820
19. Kulik L, Vouche M, Koppe S, et al. Prospective randomized pilot study of Y90+-sorafenib as bridge to transplantation in hepatocellular carcinoma. *J Hepatol*. Aug 2014; 61(2): 309-17. PMID 24681342
20. Salem R, Johnson GE, Kim E, et al. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study. *Hepatology*. Nov 2021; 74(5): 2342-2352. PMID 33739462
21. U.S. Food and Drug Administration. Summary of Safety and Effectiveness Data (SSED): TheraSphere. https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200029B.pdf. Accessed May 26, 2023.

22. Pellegrinelli J, Chevallier O, Manfredi S, et al. Transarterial Radioembolization of Hepatocellular Carcinoma, Liver-Dominant Hepatic Colorectal Cancer Metastases, and Cholangiocarcinoma Using Yttrium90 Microspheres: Eight-Year Single-Center Real-Life Experience. *Diagnostics* (Basel). Jan 14 2021; 11(1). PMID 33466706
23. Gabr A, Kulik L, Mouli S, et al. Liver Transplantation Following Yttrium-90 Radioembolization: 15-Year Experience in 207-Patient Cohort. *Hepatology*. Mar 2021; 73(3): 998-1010. PMID 32416631
24. Zori AG, Ismael MN, Limaye AR, et al. Locoregional Therapy Protocols With and Without Radioembolization for Hepatocellular Carcinoma as Bridge to Liver Transplantation. *Am J Clin Oncol*. May 2020; 43(5): 325-333. PMID 32079854
25. Tohme S, Sukato D, Chen HW, et al. Yttrium-90 radioembolization as a bridge to liver transplantation: a single-institution experience. *J Vasc Interv Radiol*. Nov 2013; 24(11): 1632-8. PMID 24160821
26. Ramanathan R, Sharma A, Lee DD, et al. Multimodality therapy and liver transplantation for hepatocellular carcinoma: a 14-year prospective analysis of outcomes. *Transplantation*. Jul 15 2014; 98(1): 100-6. PMID 24503764
27. Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. *Am J Transplant*. Aug 2009; 9(8): 1920-8. PMID 19552767
28. National Organization for Rare Disorders. Rare Disease Database: Cholangiocarcinoma. 2020; <https://rarediseases.org/rare-diseases/cholangiocarcinoma>. Accessed May 26, 2023.
29. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Hepatocellular Carcinoma. Version 1.2023. https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf. Accessed May 25, 2023.
30. Schatz DA, Porter M, Schatz E, et al. Transarterial Yttrium-90 Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis. *J Vasc Interv Radiol*. Jun 2022; 33(6): 679-686. PMID 35219834
31. Edeline J, Lamarca A, McNamara MG, et al. Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis. *Cancer Treat Rev*. Sep 2021; 99: 102258. PMID 34252720
32. Yu Q, Liu C, Pillai A, et al. Twenty Years of Radiation Therapy of Unresectable Intrahepatic Cholangiocarcinoma: Internal or External? A Systematic Review and Meta-Analysis. *Liver Cancer*. Sep 2021; 10(5): 433-450. PMID 34721506

33. Mosconi C, Solaini L, Vara G, et al. Transarterial Chemoembolization and Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma-a Systemic Review and Meta-Analysis. *Cardiovasc Intervent Radiol.* May 2021; 44(5): 728-738. PMID 33709272
34. Boehm LM, Jayakrishnan TT, Miura JT, et al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. *J Surg Oncol.* Feb 2015; 111(2): 213-20. PMID 25176325
35. Robinson TJ, Du L, Matsuoka L, et al. Survival and Toxicities after Yttrium-90 Transarterial Radioembolization of Cholangiocarcinoma in the RESiN Registry. *J Vasc Interv Radiol.* Apr 2023; 34(4): 694-701.e3. PMID 36509236
36. Chan SL, Chotipanich C, Choo SP, et al. Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres Followed by Gemcitabine plus Cisplatin for Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Single-Arm Multicenter Clinical Trial. *Liver Cancer.* Sep 2022; 11(5): 451-459. PMID 36158588
37. Kis B, Shridhar R, Mhaskar R, et al. Radioembolization with Yttrium-90 Glass Microspheres as a First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma-A Prospective Feasibility Study. *J Vasc Interv Radiol.* May 18 2023. PMID 37210030
38. Edeline J, Touchefeu Y, Guiu B, et al. Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. *JAMA Oncol.* Jan 01 2020; 6(1): 51-59. PMID 31670746
39. Riby D, Mazzotta AD, Bergeat D, et al. Downstaging with Radioembolization or Chemotherapy for Initially Unresectable Intrahepatic Cholangiocarcinoma. *Ann Surg Oncol.* Oct 2020; 27(10): 3729-3737. PMID 32472411
40. Buettner S, Braat AJAT, Margonis GA, et al. Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective Analysis. *J Vasc Interv Radiol.* Jul 2020; 31(7): 1035-1043.e2. PMID 32473757
41. Jia Z, Paz-Fumagalli R, Frey G, et al. Resin-based Yttrium-90 microspheres for unresectable and failed first-line chemotherapy intrahepatic cholangiocarcinoma: preliminary results. *J Cancer Res Clin Oncol.* Mar 2017; 143(3): 481-489. PMID 27826686
42. Mosconi C, Gramenzi A, Ascanio S, et al. Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study. *Br J Cancer.* Jul 26 2016; 115(3): 297-302. PMID 27336601
43. Rayar M, Sulpice L, Edeline J, et al. Intra-arterial yttrium-90 radioembolization combined with systemic chemotherapy is a promising method for downstaging unresectable huge intrahepatic cholangiocarcinoma to surgical treatment. *Ann Surg Oncol.* Sep 2015; 22(9): 3102-8. PMID 25623598

44. Mouli S, Memon K, Baker T, et al. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. *J Vasc Interv Radiol.* Aug 2013; 24(8): 1227-34. PMID 23602420
45. Hoffmann RT, Paprottka PM, Schön A, et al. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. *Cardiovasc Interv Radiol.* Feb 2012; 35(1): 105-16. PMID 21431970
46. Haug AR, Heinemann V, Bruns CJ, et al. 18F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90Y microspheres. *Eur J Nucl Med Mol Imaging.* Jun 2011; 38(6): 1037-45. PMID 21308371
47. Saxena A, Bester L, Chua TC, et al. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. *Ann Surg Oncol.* Feb 2010; 17(2): 484-91. PMID 19876691
48. Ibrahim SM, Mulcahy MF, Lewandowski RJ, et al. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. *Cancer.* Oct 15 2008; 113(8): 2119-28. PMID 18759346
49. Paprottka KJ, Galiè F, Ingrisch M, et al. Outcome and Safety after 103 Radioembolizations with Yttrium-90 Resin Microspheres in 73 Patients with Unresectable Intrahepatic Cholangiocarcinoma-An Evaluation of Predictors. *Cancers (Basel).* Oct 27 2021; 13(21). PMID 34771563
50. Sarwar A, Ali A, Ljuboja D, et al. Neoadjuvant Yttrium-90 Transarterial Radioembolization with Resin Microspheres Prescribed Using the Medical Internal Radiation Dose Model for Intrahepatic Cholangiocarcinoma. *J Vasc Interv Radiol.* Nov 2021; 32(11): 1560-1568. PMID 34454031
51. Ahmed O, Yu Q, Patel M, et al. Yttrium-90 Radioembolization and Concomitant Systemic Gemcitabine, Cisplatin, and Capecitabine as the First-Line Therapy for Locally Advanced Intrahepatic Cholangiocarcinoma. *J Vasc Interv Radiol.* Apr 2023; 34(4): 702-709. PMID 36521794
52. Cancer.Net. Neuroendocrine Tumors: Statistics. March 2023; <https://www.cancer.net/cancer-types/neuroendocrine-tumors/statistics>. Accessed May 26, 2023.
53. King J, Quinn R, Glenn DM, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. *Cancer.* Sep 01 2008; 113(5): 921-9. PMID 18618495
54. Ngo L, Elnahla A, Attia AS, et al. Chemoembolization Versus Radioembolization for Neuroendocrine Liver Metastases: A Meta-analysis Comparing Clinical Outcomes. *Ann Surg Oncol.* Apr 2021; 28(4): 1950-1958. PMID 33393019
55. Frilling A, Clift AK, Braat AJAT, et al. Radioembolisation with 90Y microspheres for neuroendocrine liver metastases: an institutional case series,

- systematic review and meta-analysis. *HPB (Oxford)*. Jul 2019; 21(7): 773-783. PMID 30733049
56. Devcic Z, Rosenberg J, Braat AJ, et al. The efficacy of hepatic 90Y resin radioembolization for metastatic neuroendocrine tumors: a meta-analysis. *J Nucl Med*. Sep 2014; 55(9): 1404-10. PMID 25012459
57. Egger ME, Armstrong E, Martin RC, et al. Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis. *J Am Coll Surg*. Apr 2020; 230(4): 363-370. PMID 32032719
58. Engelman ES, Leon-Ferre R, Naraev BG, et al. Comparison of transarterial liver-directed therapies for low-grade metastatic neuroendocrine tumors in a single institution. *Pancreas*. Mar 2014; 43(2): 219-25. PMID 24518499
59. Rhee TK, Lewandowski RJ, Liu DM, et al. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. *Ann Surg*. Jun 2008; 247(6): 1029-35. PMID 18520231
60. Cao CQ, Yan TD, Bester L, et al. Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. *Br J Surg*. Apr 2010; 97(4): 537-43. PMID 20205229
61. Kennedy AS, Dezarn WA, McNeillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. *Am J Clin Oncol*. Jun 2008; 31(3): 271-9. PMID 18525307
62. Memon K, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. *Int J Radiat Oncol Biol Phys*. Jul 01 2012; 83(3): 887-94. PMID 22137020
63. Paprottka PM, Hoffmann RT, Haug A, et al. Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres. *Cardiovasc Intervent Radiol*. Apr 2012; 35(2): 334-42. PMID 21847708
64. Peker A, Çiçek O, Soydal Ç, et al. Radioembolization with yttrium-90 resin microspheres for neuroendocrine tumor liver metastases. *Diagn Interv Radiol*. 2015; 21(1): 54-9. PMID 25430526
65. Jia Z, Paz-Fumagalli R, Frey G, et al. Single-institution experience of radioembolization with yttrium-90 microspheres for unresectable metastatic neuroendocrine liver tumors. *J Gastroenterol Hepatol*. Sep 2017; 32(9): 1617-1623. PMID 28132407
66. Fan KY, Wild AT, Halappa VG, et al. Neuroendocrine tumor liver metastases treated with yttrium-90 radioembolization. *Contemp Clin Trials*. Sep 2016; 50: 143-9. PMID 27520932

67. Tice J. Selective internal radiation therapy or radioembolization for inoperable liver metastases from colorectal cancer San Francisco, CA: California Technology Assessment Forum; 2010.
68. Saxena A, Bester L, Shan L, et al. A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases. *J Cancer Res Clin Oncol*. Apr 2014; 140(4): 537-47. PMID 24318568
69. Gray B, Van Hazel G, Hope M, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. *Ann Oncol*. Dec 2001; 12(12): 1711-20. PMID 11843249
70. Hendlisz A, Van den Eynde M, Peeters M, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. *J Clin Oncol*. Aug 10 2010; 28(23): 3687-94. PMID 20567019
71. Rosenbaum CE, Verkooijen HM, Lam MG, et al. Radioembolization for treatment of salvage patients with colorectal cancer liver metastases: a systematic review. *J Nucl Med*. Nov 2013; 54(11): 1890-5. PMID 24071510
72. Van Hazel G, Blackwell A, Anderson J, et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. *J Surg Oncol*. Nov 01 2004; 88(2): 78-85. PMID 15499601
73. Townsend A, Price T, Karapetis C. Selective internal radiation therapy for liver metastases from colorectal cancer. *Cochrane Database Syst Rev*. Oct 07 2009; 2009(4): CD007045. PMID 19821394
74. Mulcahy MF, Mahvash A, Pracht M, et al. Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial. *J Clin Oncol*. Dec 10 2021; 39(35): 3897-3907. PMID 34541864
75. van Hazel GA, Heinemann V, Sharma NK, et al. SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer. *J Clin Oncol*. May 20 2016; 34(15): 1723-31. PMID 26903575
76. Wasan HS, Gibbs P, Sharma NK, et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. *Lancet Oncol*. Sep 2017; 18(9): 1159-1171. PMID 28781171

77. Wolstenholme J, Fusco F, Gray AM, et al. Quality of life in the FOXFIRE, SIRFLOX and FOXFIRE-global randomised trials of selective internal radiotherapy for metastatic colorectal cancer. *Int J Cancer*. Aug 15 2020; 147(4): 1078-1085. PMID 31840815
78. Carr BI, Kondragunta V, Buch SC, et al. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. *Cancer*. Mar 01 2010; 116(5): 1305-14. PMID 20066715
79. Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. *Gastroenterology*. Jan 2010; 138(1): 52-64. PMID 19766639
80. Mokkarala M, Noda C, Malone C, et al. Comparison of Response and Outcomes of Drug-eluting Bead Chemoembolization (DEB-TACE) Versus Radioembolization (TARE) for Patients With Colorectal Cancer Liver Metastases. *Anticancer Res*. Jun 2019; 39(6): 3071-3077. PMID 31177151
81. Seidensticker R, Denecke T, Kraus P, et al. Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases. *Cardiovasc Interv Radiol*. Oct 2012; 35(5): 1066-73. PMID 21800231
82. Kennedy AS, Salem R. Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies. *Cancer J*. 2010; 16(2): 163-75. PMID 20404614
83. Liu C, Tadros G, Smith Q, et al. Selective internal radiation therapy of metastatic breast cancer to the liver: A meta-analysis. *Front Oncol*. 2022; 12: 887653. PMID 36505832
84. Aarts BM, Muñoz FMG, Wildiers H, et al. Intra-Arterial Therapies for Liver Metastatic Breast Cancer: A Systematic Review and Meta-Analysis. *Cardiovasc Interv Radiol*. Dec 2021; 44(12): 1868-1882. PMID 34322751
85. Feretis M, Solodkyy A. Yttrium-90 radioembolization for unresectable hepatic metastases of breast cancer: A systematic review. *World J Gastrointest Oncol*. Feb 15 2020; 12(2): 228-236. PMID 32104553
86. Ridouani F, Soliman MM, England RW, et al. Relationship of radiation dose to efficacy of radioembolization of liver metastasis from breast cancer. *Eur J Radiol*. Mar 2021; 136: 109539. PMID 33476965
87. Davisson NA, Bercu ZL, Friend SC, et al. Predictors of Survival after Yttrium-90 Radioembolization of Chemotherapy-Refractory Hepatic Metastases from Breast Cancer. *J Vasc Interv Radiol*. Jun 2020; 31(6): 925-933. PMID 32307310

88. Alexander H, Wen D, Chu M, et al. Selective internal radiation therapy for hepatic metastases of uveal melanoma: a systematic review. *Br J Radiol.* Jan 01 2022; 95(1129): 20210200. PMID 34757824
89. Rowcroft A, Loveday BPT, Thomson BNJ, et al. Systematic review of liver directed therapy for uveal melanoma hepatic metastases. *HPB (Oxford).* Apr 2020; 22(4): 497-505. PMID 31791894
90. Gonsalves CF, Eschelman DJ, Adamo RD, et al. A Prospective Phase II Trial of Radioembolization for Treatment of Uveal Melanoma Hepatic Metastasis. *Radiology.* Oct 2019; 293(1): 223-231. PMID 31453767
91. Xing M, Prajapati HJ, Dhanasekaran R, et al. Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy: Safety and Efficacy Cohort Study. *Am J Clin Oncol.* Feb 2017; 40(1): 27-34. PMID 25089529
92. Eldredge-Hindy H, Ohri N, Anne PR, et al. Yttrium-90 Microsphere Brachytherapy for Liver Metastases From Uveal Melanoma: Clinical Outcomes and the Predictive Value of Fluorodeoxyglucose Positron Emission Tomography. *Am J Clin Oncol.* Apr 2016; 39(2): 189-95. PMID 24441583
93. Gonsalves CF, Eschelman DJ, Sullivan KL, et al. Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience. *AJR Am J Roentgenol.* Feb 2011; 196(2): 468-73. PMID 21257902
94. Kennedy AS, Nutting C, Jakobs T, et al. A first report of radioembolization for hepatic metastases from ocular melanoma. *Cancer Invest.* Jul 2009; 27(6): 682-90. PMID 19219675
95. Klingensteins A, Haug AR, Zech CJ, et al. Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients. *Cardiovasc Interv Radiol.* Feb 2013; 36(1): 158-65. PMID 22526099
96. Piduru SM, Schuster DM, Barron BJ, et al. Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization. *J Vasc Interv Radiol.* Jul 2012; 23(7): 943-8. PMID 22609292
97. Ruohoniemi DM, Zhan C, Wei J, et al. Safety and Effectiveness of Yttrium-90 Radioembolization around the Time of Immune Checkpoint Inhibitors for Unresectable Hepatic Metastases. *J Vasc Interv Radiol.* Aug 2020; 31(8): 1233-1241. PMID 32741550
98. Michl M, Haug AR, Jakobs TF, et al. Radioembolization with Yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: efficacy, safety and prognostic factors. *Oncology.* 2014; 86(1): 24-32. PMID 24401529

99. Miller MD, Sze DY, Padia SA, et al. Response and Overall Survival for Yttrium-90 Radioembolization of Hepatic Sarcoma: A Multicenter Retrospective Study. *J Vasc Interv Radiol.* Jun 2018; 29(6): 867-873. PMID 29724518
100. Hong K, Akinwande O, Bodei L, et al. ACR-ABS-ACNM-ASTRO-SIR-SNMMI practice parameter for selective internal radiation therapy or radioembolization for treatment of liver malignancies. *Brachytherapy.* 2021; 20(3): 497-511. PMID 33824051
101. Morris VK, Kennedy EB, Baxter NN, et al. Treatment of Metastatic Colorectal Cancer: ASCO Guideline. *J Clin Oncol.* Jan 20 2023; 41(3): 678-700. PMID 36252154
102. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors. Version 2.2022.
https://www.nccn.org/professionals/physician_gls/PDF/neuroendocrine.pdf. Accessed May 24, 2023.
103. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Colon Cancer. Version 2.2023.
https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed May 26, 2023.
104. National Comprehensive Cancer Network. Melanoma: Uveal. Version 1.2023. https://www.nccn.org/professionals/physician_gls/pdf/uveal.pdf. Accessed May 23, 2023.
105. National Institute for Health and Care Excellence. Selective internal radiation therapy for primary hepatocellular carcinoma Interventional procedures guidance [IPG460]. July, 2013.
<https://www.nice.org.uk/guidance/ipg460>. Accessed May 26, 2023.
106. National Institute for Health and Care Excellence. Selective internal radiation therapies for treating hepatocellular carcinoma. Technology appraisal guidance [TA688]. March 2021. <https://www.nice.org.uk/guidance/ta688>. Accessed May 24, 2023.
107. National Institute for Health and Care Excellence. Selective internal radiation therapy for unresectable primary intrahepatic cholangiocarcinoma Interventional procedures guidance [IPG630]. October, 2018.
<https://www.nice.org.uk/guidance/ipg630>. Accessed May 22, 2023.
108. National Institute for Health and Care Excellence. Selective internal radiation therapy for unresectable colorectal metastases in the liver Interventional procedures guidance [IPG672]. March 2020.
<https://www.nice.org.uk/guidance/ipg672>. Accessed May 25, 2023.